A significant proportion of patients with colon cancer who undergo curative surgical resection develop metastatic disease. Over the last 20 years large prospective randomised studies have demonstrated a clear survival benefit for patients with stage III colon cancer who are treated with adjuvant 5FU based chemotherapy. At the present time 6 months of 5FU and leucovorin is generally considered the standard adjuvant therapy. For stage II disease the routine use of adjuvant treatment remains controversial. Newer drugs such as oxaliplatin, irinotecan, and the oral fluoropyrimidines have proven active in advanced colorectal cancer and are currently being evaluated in the adjuvant setting. Molecular markers for this disease are being identified and may help define those patients who would benefit from therapy. The integration of adjuvant immunotherapy with conventional chemotherapy offers the potential to improve the long-term outcome for surgically resected colon cancer.
INTRODUCTION
Each year approximately 300,000 deaths from colorectal cancer occur world-wide (1). The incidence is notably higher in developed countries (2). Approximately 70-80 % of new cases of colon cancer undergo potentially curative surgery, but 40 % of these patients develop metastatic disease due to undetected micrometastatic disease at the time of surgery. Thus the concept of adjuvant chemotherapy was developed to eradicate micrometastases and prevent disease recurrence. This has led to a large number of clinical trials since the 1950's evaluating adjuvant chemotherapy.
STAGE III COLON CANCER
Despite the large number of clinical trials conducted, a meta-analysis performed in 1988 concluded that there was no clear evidence of a survival benefit for adjuvant chemotherapy. When the analysis included only those trials utilising 5FU, there was a trend towards a statistically significant survival advantage (3). There then followed a series of large randomised studies, which defined the role of adjuvant chemotherapy in colon cancer (Table 1) . The National Surgical Adjuvant Breast and Bowel Project (NSABP) study C-01 demonstrated a survival benefit for stage II and III patients treated with semustine, 5FU and vincristine (MOF) versus surgery alone (4). Another large co-operative group trial of 401 patients reported a marked reduction in recurrence rate for patients with stage II and III disease receiving the combination of 5FU and levamisole and in a separate analysis of the stage III subgroup the improvement in survival reached borderline significance (5). These data were then confirmed in the larger Intergroup (INT-0035) trial of 929 patients which demonstrated a 41 % reduction in the risk of cancer recurrence for the stage III subgroup with the same chemotherapy reg- b) for 12 months p = 0.09 p = 0.09 yet b) 5FU (425 mg/m 2 )/LV (20 mg/m 2 )5 9 %6 6 % b) D1-5 every 4-5 weeks (b vs c) (b vs c) b) for 6 months p = 0.68 p = 0.56 c) 5FU/LV (500 mg/m 2 ) weekly × 60 %6 5 % b) 6 every 8 weeks for 8 months (a vs c )( a vs c) p = 0.18 p = 0.20 d) 5FU (425 mg/m 2 )/LV (20 mg/m 2 )/ 60 %6 7 % b) Lev D1-5 every 4 weeks (a vs d) (a vs d) b) for 6 months p = 0.014 p = 0.24 (b vs d) (b vs d) p = 0.24 imen and a 33 % decrease in the relative risk of mortality (6). These results led to a recommendation from the National Institute of Health (NIH) consensus meeting that 5FU/levamisole should be given as adjuvant chemotherapy in patients with surgically resected stage III colon cancer (7). Long term follow up of the Intergroup study (INT-0035) confirmed the benefit in recurrence rate and survival with 5FU/levamisole (8).
Intergroup
Levamisole is an antihelminthic agent and the mechanism by which it potentiates 5FU remains obscure. In contrast, leucovorin (LV) has the potential to increase the efficacy of 5FU by stabilising the thymidylate synthase complex. It was evaluated in several trials in metastatic colorectal cancer resulting in a higher response rate compared to bolus 5FU alone (9). This prompted a series of trials evaluating 5FU/LV as adjuvant therapy. The NSABP C-03 randomised 1081 patients to the MOF regimen versus 5FU/leucovorin for 1 year and showed a 9 % survival gain for the latter combination without incurring any additional toxicity (10) . In addition the NCCTG enrolled 319 patients to receive 5FU/low dose LV for just 6 months versus surgery alone. The trial was closed prematurely following the NIH consensus recommendation for adjuvant chemotherapy with 5FU/ levamisole as a standard treatment for stage III patients (11) . Nevertheless, a significant improvement in survival (11 %) and recurrence rate was observed in the treatment group. The International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) pooled data from 3 randomised prospective trials investigating a similar chemotherapy schedule of 6 months of 5FU and high dose LV which produced a 21 % reduction in mortality at long term follow up. Subgroup analysis demonstrated a 30 % reduction in mortality for stage III patients but only 8 % for stage II patients (12) .
These trials demonstrated that 5FU/LV were indeed an active regimen but the following questions needed to be addressed: a) is high dose LV superior to low dose LV? b) does 12 months of 5FU/LV offer any survival advantage over 6 months? c) is 5FU/ LV superior to 5FU/levamisole? Several trials were conducted to address these issues. A large Intergroup trial (INT-0089) of 3571 (stage II and III) patients randomised subjects to a) the standard 5FU/levamisole, b) 7-8 months of low dose LV/5FU according to the Mayo regimen, c) high dose LV/5FU weekly for 6 out of every 8 weeks for 4 cycles, d) 5FU/levamisole/ LV (Mayo regimen plus standard levamisole). The findings of this trial were that the shorter courses of 5FU/LV were equivalent to 1 year of 5FU/levamisole, and that 5FU/LV/levamisole produced superior overall survival compared to the standard therapy of 5FU/levamisole but was inferior to 5FU/low dose LV (13) . Based on these data the Intergroup concluded that 5FU/LV for 6 months should be the standard of care for resected high-risk colon cancer patients.
The NCCTG group collaborated with the National Cancer Institute of Canada Clinical Trials Group (NCIC) in a study of 891 patients designed to evaluate whether 6 months of chemotherapy was equiva-lent to 12 months, and to assess the efficacy of the triple drug combination 5FU/LV/levamisole. No survival difference was seen with 6 versus 12 months of chemotherapy. Furthermore they demonstrated that 6 months of 5FU/levamisole was an inferior regimen and should not be used (14) . The NSABP C-04 trial reported a superior disease free survival rate (65 % vs 60 %, p = 0.04) and a trend towards superiority for overall survival with 5FU/LV compared to 5FU/levamisole (15) . In keeping with the other studies no survival benefit was observed for the addition of levamisole to 5FU/LV.
Taken together the evidence from these trials showed that low dose LV is equivalent to high dose LV, 5FU/LV administered over 6 months is of similar efficacy to 12 months. 5FU/levamisole for 6 months is an inferior regimen, the 2 schedules of 5FU/LV (Mayo clinic: 5FU 425 mg/m 2 and LV 20mg/m 2 days 1-5 every 4 weeks for 6 months, Roswell Park: 5FU 500 mg/m 2 and LV 500 mg/m 2 weekly × 6 weeks every 8 weeks for 4 cycles) differ in toxicity but not survival, and that the incorporation of levamisole to 5FU/LV does not improve long term outcome.
Meanwhile further confirmatory studies were carried out in Europe ( Table 2 ). The Netherlands Adjuvant Colon Cancer Project (NACCP) study randomised 1029 patients to either 1 year of 5FU/levamisole or observation. They reported a significant overall survival gain (10 %) for the chemotherapy arm in stage III patients (16) . A German study of 702 patients evaluated 1 year of 5FU/levamisole versus 12 months of 5FU/LV in stage III patients. After a median follow up of 46.5 months they showed a significant improvement in disease free and overall survival and for 5FU/LV (17) . The largest adjuvant study conducted thus far is the QUASAR (Quick And Simple And Reliable) study which recruited 4927 patients (colon and rectum), the majority from the United Kingdom (18) . This was a 2 × 2 factorial design where patients were randomised to receive 5FU plus low or high dose LV and with levamisole or placebo. This was a well designed trial with the aim of facilitating large scale recruitment and thus involved a minimal workload for the participating clinical investigators, and management aside from the study treatment was at the clinicians discretion. They reported no survival difference between high and low dose leucovorin. This trial also reinforced the findings of INT-0089 and NSABP C-04 that the addition of levamisole to 5FU/LV does not confer any survival advantage over 5FU/LV.
STAGE II COLON CANCER
The use of adjuvant chemotherapy in resected stage II disease remains controversial. There are 2 large analyses that have focused on this issue. The IMPACT B2 study pooled data from 5 trials comprising of 1016 patients with stage II disease randomised between 5FU/LV and observation (19) . The median follow up was 5.75 years and the patients receiving chemotherapy did not experience any survival im-provement. The hazard ratio at 5 years was 0.83 [90 % confidence interval (CI) 0.72-1.07] for event free survival and 0.86 (90 % CI 0.68-1.07) for overall survival. Poor prognostic factors identified included increasing age and poorly differentiated tumours. Thus this data did not support the routine use of 5FU/LV as adjuvant therapy for stage II colon cancer however the analysis was of insufficient power to detect a small survival difference between chemotherapy and observation.
In a further analysis carried out by the NSABP group, collective data was pooled from C-01, C-02, C-03 and C-04 and examined according to tumour stage (20) . The relative magnitude of the reduction in mortality, recurrence and disease free survival was similar for stage II and III patients although the number of patients with stage II disease was not enough to detect a small benefit from treatment in this group. In addition, data was combined from the superior and inferior arms of these 4 trials and a direct comparison was made. The results demonstrated an improvement in disease free and overall survival supporting the use of adjuvant chemotherapy in stage II colon cancer patients. However these individual trials involved widely differing treatments. In summary, these two large analyses produced conflicting results and neither analysis demonstrated a clear benefit for adjuvant chemotherapy in stage II colon cancer. More recently the NACCP trial reported in 2001 lends further support towards the use of adjuvant chemotherapy for this group of patients. In this study stage II patients receiving chemotherapy with 5FU/levamisole also derived a significant survival benefit with a 19 % risk reduction in death (16) .
In contrast a SEER-Medicare cohort of 3,725 of stage II patients was retrospectively analysed in the US. Survival was compared for treated and untreated patients, 31 % of patients received adjuvant chemotherapy. The 5 year survival for treated patients was not significantly superior to that of untreated patients [74 % versus 72 %, hazard ratio for survival 0.93 (95 % CI 0.81-1.07)] (21) .
Overall, there is still no global consensus regarding the use of adjuvant chemotherapy in stage II colon cancer. The available evidence does not clearly define its role for this stage of disease. The existing randomised trials were of insufficient power to detect a small survival difference. In order to identify an absolute survival difference of 4 % at 5 years, the minimum number of patients required would be 4000.
In the meanwhile oncologists are justified in considering adjuvant chemotherapy for stage II patients with high risk features namely perforation, intestinal obstruction, extramural venous or lymphatic invasion and perineural invasion, providing no medical contraindications exist. However, where possible b) for 6 months p = 0.94 p = 0.43 b) 5FU (370 mg/m 2 )/ 24633 5.8 %7 1 % b) LV(25 mg fixed dose) b) weekly or 4 weekly b) for 6 months c) 5FU (370 mg/m 2 )/ 24293 7 %6 9.4 % b) high or low dose LV/ (c vs d) (c vs d) b) Lev weekly or 4 weekly p = 0.16 p = 0.06 b) for 6 months d) 5FU (370 mg/m 2 )/high or 24343 4.9 %7 1.5 % b) low dose LV/placebo weekly b) or 4 weekly for 6 months these patients should be entered into randomised studies.
ADJUVANT CHEMOTHERAPY WITH INFUSED 5FU
In metastatic colorectal disease prolonged infusion 5FU produced a small but significant survival advantage and less haematological toxicity compared to bolus 5FU/LV (22) . This stimulated its evaluation in the adjuvant setting.
There are 2 recent studies that have examined daily-protracted venous infusion (PVI) of 5FU. The South West Oncology group (SWOG) study 9415/ INT-0153 compared PVI 5FU (250mg/m 2 ) with levamisole for 27 weeks versus 6 months of bolus 5FU/ LV/levamisole. At 3 years an interim analysis showed no survival benefit for the PVI 5FU arm, furthermore this was improbable even if the target accrual was achieved, thus the study closed prematurely (23) . A study from the UK randomised 716 patients with stage II and III disease to 6 months of 5FU/LV as per the Mayo regimen or 12 weeks of PVI 5FU (300 mg/m 2 ) (24) . The relapse free and overall survival were similar in both arms. PVI 5FU had a more acceptable toxicity profile with fewer cases of stomatitis, diarrhoea, neutropenia and alopecia.
The GERCOR group randomised 905 patients in a 2 × 2 factorial design, firstly to 2 weekly infused 5FU/LV or 4 weekly bolus 5FU/LV, and then to 24 or 36 weeks of treatment. There were no significant differences in disease free survival with either treatment arm (HR 1.042, 95 % CI: 0.814-1.335) or between 24 or 36 weeks of therapy (HR 0.942; 95 % CI 0.735-1.21) (25) .
To date in the adjuvant setting no study has shown a significant survival advantage for infused 5FU versus bolus regimens. Nevertheless infused 5FU has proved to be of at least equivalent efficacy to bolus 5FU/LV with less toxicity which makes it an attractive regimen. Two large European adjuvant studies are underway utilising the 2 weekly infused 5FU/LV schedule as the control arm and in partnership with oxaliplatin or irinotecan in the comparator arm.
NEW DRUGS IN ADJUVANT TREATMENT
A number of new drugs and regimens are under investigation for this cohort of patients and a summary is shown in Table 3 . The combination of 5FU/LV with irinotecan has produced improved survival in comparison with 5FU/LV for metastatic disease and has generated interest in its use in the adjuvant setting (26) . Currently 2 studies are evaluating this combination with a 5FU/LV regimen as the reference comparator-CALGB C89803 (closed) and PETACC -3 (active). Recently concerns have been raised over the safety of these regimens after a number of unexpected early deaths were encountered with bolus 5 FU/LV plus irinotecan in an Intergroup study N9741 for advanced disease (27) . The early death rate was reviewed for patients receiving irinotecan combined with bolus 5FU/LV in the C 89803 study. This was also high (2.2 %) compared to treatment related mortality of 0-0.8 % in other adjuvant studies. In contrast thus far the data from the PETTACC -3 study does not show any excess mortality.
Oxaliplatin is a third generation platinum derivative. The results when combined with 5FU/LV in advanced colorectal cancer demonstrate an improvement in response rate and disease free survival compared to 5FU/LV alone (28) . Furthermore, 5FU/LV/ oxaliplatin has now demonstrated a significant survival advantage (hazard ratio 0.67, p = 0.002) compared to 5FU/LV/irinotecan in a large randomised Intergroup study of 795 patients with advanced colorectal cancer (29) . It has been incorporated in adjuvant colon studies in the USA (NSABP C-07) and Europe -(MOSAIC).
The oral fluoropyrimidines mimic the activity of continuous intravenous infusions of 5FU, maintaining prolonged exposure to 5FU and reduced overall toxicity. They have been integrated into the treatment of metastatic colon cancer with promising results. Capecitabine has shown equivalent survival to bolus 5FU/LV in advanced colorectal cancer (30, 31) . Uracil-tegafur (UFT) another member of this class of drugs, has also demonstrated comparable survival to bolus 5FU/LV in advanced colon cancer (32) . Their role in the adjuvant setting remains to be determined and is being addressed in two large randomised studies X-ACT and NSABP C-06.
The murine monoclonal antibody edrecolomab (17-1A) recognises an epithelial -cell adhesion molecule (Ep-CAM) which is expressed in several types of carcinoma. It first showed promising clinical activity in a German adjuvant study for stage III colorectal cancer patients (33) . At long term follow up there was a significant reduction in mortality (32 %) and disease recurrence (23 %) for patients receiving edrecolomab versus surgery alone. These data prompted adjuvant studies evaluating the antibody in stage II and III colon cancer.
A large international study is ongoing assessing edrecolomab in stage II colon cancer. Recently a large intercontinental study has reported their experience with this agent in stage III colon cancer. After surgery 2761 patients were randomised to edrecolomab alone, edrecolomab plus bolus 5FU/LV or bolus 5FU/LV alone. They found that the addition of edrecolomab to chemotherapy did not improve overall survival [hazard ratio 0.94 (95 % CI: 0.76-1. 15) ]. Furthermore, the overall survival on edrecolomab monotherapy was significantly inferior to that of chemotherapy alone [hazard ratio 0.82 (95 % CI: 0.67-1.00), p = 0.05] (34) . However an American randomised study of 1839 patients demonstrated a significant improvement in overall survival [3 yr. OS 81.6 % (95 % CI: 78.7-84.4) versus 78.9 % (95 % CI 75.9-81.9)] with the addition of edrecolomab to 5FU based chemotherapy for stage III disease. Curiously there was no improvement in disease free survival with this combination (35) . Therefore the benefit of edrecolomab for stage III colon cancer is uncertain.
DEFINING PATIENTS AT HIGH RISK OF RECURRENCE
A specific patient population at high risk of recurrence has yet to be defined particularly in stage II disease. Molecular markers that could predict sensitivity to chemotherapy and long term outcome may help identify this group and thus the search is underway.
There has been much interest in the genetic pathways leading to colorectal cancer in recent years. One important pathway identified involves defects in DNA mismatch repair genes and these tumours are characterised by microsatellite instability (MSI). Microsatellites are repetitive DNA sequences that tend to mutate at predictable points if DNA mismatch repair is deficient and thus can be used as markers. These tumours appear to have a better prognosis. A recent study showed a 90 % 5-year survival after adjuvant 5FU/levamisole in patients with Dukes C co- (36) . Following this, an analysis of archival tissues from the NSABP trials (C-01, C-02, C-03, and C-04) was performed to evaluate the prognostic role of MSI. There was a trend towards improved survival in the MSI group and this held true for patients receiving surgery with or without the addition of chemotherapy (37) .
However a pooled molecular analysis on 570 tumour specimens from several randomised studies found a significant interaction between MSI expression and treatment efficacy (38) . Patients with MSI tumours had a better 5 year survival than microsatellite stable (MSS) tumours in the absence of chemotherapy (p = 0.004) but not in the presence of 5FU based chemotherapy. Interestingly for the MSS tumours the use of adjuvant chemotherapy led to a significant improvement in survival whereas it was associated with a worse outcome in MSI tumours although the latter subgroup represented a small per-centage of the whole cohort. These are markedly contrasting results and further confirmatory studies are required to resolve this issue.
A Canadian study performed bcl-2 staining on 76 patients with stage II colon cancer who had undergone surgery (39) . Those patients who were bcl-2 positive had a similar disease free survival but a significant improved overall survival compared to the negative cases (p = 0.038). Thus the authors concluded that bcl-2 expression might have a role in identifying stage II patients who would benefit from adjuvant chemotherapy.
The detection of carcinogenic embryonic antigen (CEA) messenger RNA is another area of interest to identify micrometastases and studies utilising the reverse transcriptase polymerase chain reaction (RT-PCR) assay are underway. Sentinel lymph node mapping of colorectal cancer is also being evaluated in conjunction with molecular analysis to identify occult nodal micrometastases.
CONCLUSION
Adjuvant chemotherapy is now established for stage III colon cancer. The results of ongoing trials are awaited and in the meanwhile 5FU/LV given for 6 months should be the reference comparator for any future randomised studies. The role of adjuvant chemotherapy in stage II colon cancer has not yet been clearly defined. The relatively small number of stage II patients in the Dutch study is unlikely to change clinical practice amongst the oncological community. However these data support the benefit of adjuvant chemotherapy in this setting and reinforce its use for those patients with adverse histological features. Overall, the magnitude of benefit in this group is likely to be smaller and thus large-scale collaborative trials are required to detect a clinically significant survival advantage.
Attempts to improve the outcome of this disease continue with targeted therapy opening up a new avenue of treatment. The development of reliable prognostic and predictive molecular markers in the future will enable treatment to be tailored according to the individual tumour. The integration of new chemotherapy agents and targeted treatment offer the potential to improve the overall survival and minimise toxicity for these patients.
